Impact of Number of Cycles of Collagenase Clostridium Histolyticum on Outcomes in Patients With Peyronie's Disease

详细信息    查看全文

• 作者：James Anaissie ; Faysal A. Yafi ; Kenneth J. DeLay ; Elizabeth J. Traore ; Suresh C. Sikka ; Wayne J.G. Hellstrom ; ^{whellst@tulane.edu}
• 刊名：Urology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：100
• 期：Complete
• 页码：125-130
• 全文大小：300 K
• 卷排序：100

文摘

To analyze the impact of the number of cycles of collagenase Clostridium histolyticum (CCH) intralesional injection therapy on outcomes to further characterize CCH therapy.MethodsWe conducted a retrospective review of the records of all patients treated with CCH for Peyronie disease between April 2014 and March 2016. Collected variables included demographics, pre- and posttreatment sexual function, penile curvature, penile vascular findings, and treatment outcomes.ResultsA total of 77 patients were included in the study, of which 41 (53%) completed 4 cycles of treatment, consisting of 8 total injections. For all-comers regardless of numbers of cycles, curvature improved from 58.2° (standard deviation = 17.9°, range = 30°-105°) pre-treatment to 41.0° (standard deviation = 17.0°, range = 0°-85°) posttreatment (P < .001). In a repeated measures model, penile curvature improved significantly following the first 3 cycles, but not the fourth. Patients who had a ≥20% final reduction in curvature had a significantly greater change in curvature following the first injection (−16.2° vs −5.8°, P < .001).ConclusionIntralesional CCH therapy is an effective minimally invasive treatment for Peyronie disease, although the therapeutic benefit may decline after the third cycle of treatment. Patients with ≥20% reduction in curvature at the conclusion of treatment documented a greater curvature improvement after the first cycle and received more cycles of CCH.